MedTrace Logo

IVIg for Demyelination in Diabetes Mellitus

NCT02372149 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-11-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether intravenous immunoglobulin (IVIg) is an effective intervention for patients with diabetes, peripheral neuropathy, and demyelination on nerve conduction studies. All patients will receive both IVIg and placebo for 3 months each, with a 3 month washout period in between.

Conditions

Interventions

DRUG

10% intravenous immunoglobulin (IVIg)

DRUG

0.9% sodium chloride

Sponsors & Collaborators

  • University Health Network, Toronto

    collaborator OTHER

  • University of Toronto

    lead OTHER

Principal Investigators

  • Ari Breiner, MD, FRCPC · University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02372149 on ClinicalTrials.gov